CoChat

Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors

Cramer, Peyton, Bresalier, Robert S. · 2017 · Current Gastroenterology Reports

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Purpose of review Gastrointestinal complications are very common in patients undergoing cancer treatment. Some of these complications can be life threatening and require prompt and appropriate diagnosis and treatment. The purpose of this review is to address luminal gastrointestinal and hepatic complications associated with a new class of anticancer drugs, immune checkpoint inhibitors (CPIs), and focuses on the identification, evaluation, and management of the complications associated with this class of drugs.Recent findings It is now recognized that immune checkpoint inhibitors are frequently associated with luminal GI side effects such as diarrhea and enterocolitis and hepatic complications such as hepatitis. While colitis associated with CPIs, to some extent, mimics that found in idiopathic inflammatory bowel disease, the complex interplay of genes, the environment, the immune system, and the microbiome make it difficult to fully differentiate these conditions clinically. CPI-induced hepatitis is most often associated with a pattern of hepatocellular injury with panlobular hepatitis. A variety of biomarkers have been proposed to predict an adverse response to CPIs and are under investigation. It has been proposed that alterations in the microbiome may impact the risk of developing colitis, and these studies are reviewed. In contrast to idiopathic chronic inflammatory bowel disease, CPI-induced colitis is often reversible if rapidly treated in accordance with the immune-mediated adverse reaction management guidelines. Treatment algorithms have been suggested but are, to some extent, empiric and based on algorithms for the treatment of idiopathic inflammatory bowel disorders. CPIs may be associated with significant GI complications which impact their successful use in the treatment of neoplastic diseases. Much of what we currently know about the mechanisms and treatment of these complications is empiric and extrapolated from experience with idiopathic inflammatory bowel disease and other immune disorders. Current research focuses on understanding genetic predisposition and the role of the microbiome and identifying predictive risk markers for developing complications.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11894-017-0540-6

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 54 references

Cited by

See all 175

Metadata

Authors
Cramer, P., & Bresalier, R. S.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Bresalier, Robert S.
Venue
Current Gastroenterology Reports
Published
2017-01
Volume
19
Issue
1
Pages
3-3
ISSN
  • 1522-8037 (ISSN-L)
  • 1534-312X
OpenAlex
W2581935274
Cited by
167
References
54
Citations by year
2026: 7 · 2025: 8 · 2024: 11 · 2023: 13 · 2022: 23 · 2021: 28 · 2020: 18 · 2019: 32 · 2018: 18 · 2017: 9
FWCI
2.21
Type
journal article
Language
en
Open access
closed
Locations
  • Current Gastroenterology Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
immune checkpoint inhibitors, immune-related adverse events, diarrhea, enterocolitis, inflammatory bowel disease, gut microbiota, predictive biomarkers, hepatocyte injury, treatment algorithm
MeSH terms
Gastrointestinal Microbiome, Antibodies, Monoclonal, Antineoplastic Agents, Colitis, Diagnosis, Differential, Gastrointestinal Diseases, Humans, Immunotherapy, Neoplasms, Inflammatory Bowel Diseases, Chemical and Drug Induced Liver Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. https://app.cochat.ai/papers/10.1007/s11894-017-0540-6
The paper
Cramer, P., & Bresalier, R. S. (2017). Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. Current Gastroenterology Reports. https://doi.org/10.1007/s11894-017-0540-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.